Mild cognitive impairment. Mild cognitive impairment, so stated
Conditions
Interventions
Intervention 1: First intervention group: In this group, individuals will receive one capsule containing 300 mg of elemental magnesium (500 mg of magnesium in the form of magnesium oxide) daily for 8
Sponsors
Shiraz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Inclusion criteria
Inclusion criteria: Age 65 years and older Suffering from mild cognitive impairment; means obtaining a score of 22 to 25 in the Mini-ACE cognitive function evaluation form Ability and willingness to participate in the study No smoking/alcohol and drug addiction Absence of severe renal/hepatic/pulmonary insufficiency, uncontrolled diabetes, severe neurological or psychiatric disorders such as Bipolar disorder, Parkinson's disease, Dementia, unstable thyroid disease; Immune disorders such as HIV/AIDS Not following specific diets (such as Ketogenic, Vegetarian, etc.) No current use of medications that interact with magnesium, such as muscle relaxants, Penicillamine, Corticosteroids, Methyldopa, Magnesium-containing antacids, or other magnesium-containing products Participants must have not taken antibiotics and probiotic, magnesium, and antioxidant supplements for at least 2 weeks prior to the start of the study
Exclusion criteria
Exclusion criteria: Changes in usual diet and medication Starting antibiotic therapy The occurrence of any side effects that stops when the intervention is discontinued. Less than 80% adherence to supplement use Unwillingness to continue cooperation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cognitive function score in the Mini-Addenbrooke’s Cognitive Examination (M-ACE) questionnaire. Timepoint: Cognitive function assessment before the start of the intervention and 8 weeks later (end of the study). Method of measurement: Mini-Addenbrooke’s Cognitive Examination (M-ACE) questionnaire.;Serum level of high-sensitivity C-reactive protein. Timepoint: Measurement of serum levels of high-sensitivity C-reactive protein before the start of the intervention and 8 weeks later (end of study). Method of measurement: Through a blood test and ELISA method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life score in the Older People's Quality of Life questionnaire (OPQOL-brief). Timepoint: Quality of life assessment before the start of the intervention and 8 weeks later (end of the study). Method of measurement: Older People's Quality of Life questionnaire-brief version (OPQOL-brief).;Frailty score in the Frailty Syndrome Checklist 5-Items in Frail Older Adults in Iran (Fried's Five-Point Frailty Test). Timepoint: Frailty assessment before the start of the intervention and 8 weeks later (end of the study). Method of measurement: Frailty score in the Frailty Syndrome Checklist 5-Items in Frail Older Adults in Iran (Fried's Five-Point Frailty Test). | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactRahil Ranjbar
Shiraz University of Medical Sciences
Outcome results
None listed